Neumora Therapeutics, Inc.

Equities

NMRA

US6409791000

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-19 pm EDT 5-day change 1st Jan Change
10.18 USD -3.51% Intraday chart for Neumora Therapeutics, Inc. -24.93% -40.29%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Advance Premarket Monday MT
Sector Update: Health Care MT
Investors Shrug Off Geopolitical Concerns, Driving Premarket Gains for US Equity Futures MT
Upcoming Earnings Buoy Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday MT
Top Premarket Decliners MT
Neumora Therapeutics' Phase 1 Trial of Potential Brain Disease Drug on Hold After Convulsions in Rabbits MT
Neumora Shares Slide Premarket as FDA Puts Early Study of Schizophrenia Drug on Hold DJ
Neumora's early-stage schizophrenia drug study put on hold RE
U.S. FDA places clinical hold on Neumora's schizophrenia drug study RE
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study CI
JPMorgan Adjusts Price Target on Neumora Therapeutics to $22 From $20, Maintains Overweight Rating MT
Neumora Therapeutics, Inc.(NasdaqGS:NMRA) added to S&P Global BMI Index CI
Certain Common Stock of Neumora Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 12-MAR-2024. CI
Certain Stock Options of Neumora Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 12-MAR-2024. CI
RBC Raises Price Target on Neumora Therapeutics to $31 From $24, Keeps Outperform, Speculative Risk MT
Neumora Therapeutics Q4 Loss Narrows MT
Neumora Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Neumora Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Neumora Therapeutics Names Kaya Pai Panandiker as Chief Commercial Officer MT
Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer CI
Neumora Therapeutics, Inc.(NasdaqGS:NMRA) added to S&P TMI Index CI
Deutsche Bank Initiates Coverage on Neumora Therapeutics With Hold Rating, $13 Price Target MT
Neumora Therapeutics, Inc. Appoints Jason Duncan as Chief Legal Officer CI
Neumora Therapeutics Starts Phase 1 Trial of NMRA-266 as Potential Treatment of Schizophrenia, Neuropsychiatric Disorders MT
Neumora Therapeutics, Inc. Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study CI
Chart Neumora Therapeutics, Inc.
More charts
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
10.18 USD
Average target price
24.71 USD
Spread / Average Target
+142.75%
Consensus
  1. Stock Market
  2. Equities
  3. NMRA Stock
  4. News Neumora Therapeutics, Inc.
  5. Neumora Therapeutics Names Kaya Pai Panandiker as Chief Commercial Officer